Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
May 8, 2025
BioUtah president and CEO, Kelvyn Cullmore, recently penned an op-ed published in the Deseret News on the need to fix the Inflation Reduction Act’s (IRA) “pill penalty.” The pill penalty refers to a provision in the IRA that allows Medicare to impose government drug negotiations for small-molecule drugs (like pills and tablets) years sooner than for large-molecule drugs (biologics). Cullilmore notes that there are times when government interventions create unanticipated negative consequences. Such is the case with this IRA policy.
Recent News
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
- Sera Prognostics Appoints Scott Gleason CFO
- Merit Medical Announces Global Operations Leadership Transition
- Utah Life Sciences Innovation Caucus Breakfast
- Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors
